Developer docs
API playgroundTry for free, no card

Search company profiles

AAVantgarde Bio

Full company profile

uuid0000cyv

Namestring
AAVantgarde Bio
Legal namestring
AAVantgarde Bio s.r.l.
Websiteurl
aavantgarde.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

AAVantgarde Bio s.r.l. is a clinical-stage biotechnology company founded in 2021 as a spin-off of the Telethon Institute of Genetics and Medicine (TIGEM) and the University of Naples 'Federico II', developing one-time subretinal gene therapies for inherited retinal disorders (IRDs) — specifically Stargardt disease (ABCA4 mutations) and retinitis pigmentosa associated with Usher Syndrome Type 1B (MYO7A mutations). The company is headquartered in Milan with operations in London and is led by CEO Natalia Misciattelli and founder/CSO Prof. Alberto Auricchio.

The company's core technology is two proprietary, AAV-based large-gene delivery platforms that overcome the ~4.7–5 kb cargo limit of conventional AAV vectors: the Dual Hybrid Platform, which splits a therapeutic transgene across two AAV8 vectors that reconstitute a full-length mature mRNA via ITR/HR-mediated concatemerization and splicing (used in AAVB-081 / LUCE-1 for Usher 1B); and the Intein-mediated Protein Trans-splicing Platform, which uses split inteins to reassemble large therapeutic proteins inside target cells (used in AAVB-039 / CELESTE for Stargardt). Both platforms have been validated in mice, pigs, non-human primates and human retinal organoids. The clinical pipeline comprises AAVB-081 (Phase 1/2 LUCE-1, fully enrolled) and AAVB-039 (Phase 1/2 CELESTE, IND-cleared), supported by the STELLA natural history study in ~120 Stargardt subjects. Pipeline placeholders AAVB-OPHTHA and AAVB-OTHER extend the platforms to additional IRDs and non-ophthalmic monogenic indications (inner ear, CNS).

AAVantgarde is currently pre-revenue. Funding to date totals approximately $202 million across a 2021 Sofinnova-Telethon seed, a €61M Series A in June 2023, and a $141M Series B in November 2025 co-led by Schroders Capital, Atlas Venture and Forbion, with new investors including Amgen Ventures. Future revenue is expected from commercialization of AAVB-081 and AAVB-039 and from platform out-licensing (a Dual Hybrid license for hereditary hearing loss has already been signed with a US company). Manufacturing is contracted to AGC Biologics; clinical operations span the US, UK and Europe; and the company partners with 14+ global patient advocacy organizations for trial recruitment and disease awareness.

Short descriptiontext

AAVantgarde Bio is a clinical-stage biotechnology company developing one-time subretinal gene therapies for inherited retinal disorders — Stargardt disease and Usher Syndrome Type 1B — using proprietary Dual Hybrid and Intein AAV platforms that deliver large therapeutic genes exceeding conventional AAV packaging capacity.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMilano, Italy
HQ citystring
Milano
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy development, ophthalmic biotechnology, adeno-associated virus vectors, inherited retinal disorders, clinical-stage biopharmaceutical
Industry3 codes
PRIMARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
Product category
Ophthalmic Gene Therapy
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pre-revenue clinical-stage development
TypeSubscription Recurring
Description

AAVantgarde is currently pre-revenue, with no approved products. The company funds clinical development (LUCE-1, CELESTE, STELLA) entirely from venture capital and grants; future revenue is expected from commercialization of its lead gene therapies (AAVB-081 for Usher 1B and AAVB-039 for Stargardt) once approved, and from potential platform out-licensing to other indications.

aavantgarde.com
2Platform out-licensing (Dual Hybrid)
TypeLicensing Royalties
Description

The Dual Hybrid platform has been licensed to a US company for hereditary hearing loss applications, generating potential upfront, milestone, and royalty income. This represents an early-stage licensing/royalty revenue stream derived from the company's proprietary AAV delivery technology.

fondazionetelethon.it
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Dual Hybrid Platform
Description

Proprietary AAV-based large gene delivery platform that splits a therapeutic transgene across two vectors and reassembles it at the DNA level via splice donor/acceptor signals and a highly recombinogenic region; used in the AAVB-081 program for Usher 1B.

aavantgarde.com
+3 more records
Core offering1 text field

AAVantgarde Bio is a clinical-stage biotechnology company developing investigational gene therapies for inherited retinal disorders (IRDs) using two proprietary dual-vector AAV delivery platforms — the Dual Hybrid Platform and the Intein Platform — that overcome the ~4.7–5 kb cargo limit of conventional AAVs to deliver large therapeutic transgenes such as MYO7A and ABCA4. The lead clinical programs are AAVB-081 (for retinitis pigmentosa associated with Usher Syndrome Type 1B) and AAVB-039 (for Stargardt disease), both pursued via subretinal administration of AAV8-based dual vectors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 15 Usher syndrome patients treated to date via the Dual Hybrid approach in the LUCE-1 study, with a very good safety profile and early efficacy signal reported
+3 more records
Product overview1 text field

AAVantgarde Bio is a clinical-stage biotechnology company built around a platform-plus-candidates architecture: two proprietary large-gene AAV delivery platforms (the Dual Hybrid Platform and the Intein Platform) underpin a focused pipeline of investigational gene therapies. The Dual Hybrid Platform powers AAVB-081, the lead product for retinitis pigmentosa associated with Usher Syndrome Type 1B (Usher 1B), tested in the LUCE-1 Phase 1/2 trial; the Intein Platform powers AAVB-039, the second product for Stargardt disease, tested in the CELESTE Phase 1/2 trial and supported by the STELLA natural history study. The company is also extending its reach via two early pipeline placeholders — AAVB-OPHTHA (additional monogenic IRDs) and AAVB-OTHER (non-ophthalmic monogenic indications such as inner ear and CNS). The spin-off of Fondazione Telethon/TIGEM and University of Naples Federico II focuses the entire offering on restoring visual function and halting disease progression in IRDs caused by mutations in large genes that exceed conventional AAV packaging capacity.

Product and service6 records
1AAVB-081
CategoryInvestigational gene therapy candidate (lead clinical program)
Description

AAVB-081 is AAVantgarde's lead investigational gene therapy product: an intra-retinal AAV8-based dual hybrid gene therapy delivering MYO7A, the gene associated with Usher Syndrome Type 1B (Usher 1B). It is being investigated in the LUCE-1 Phase 1/2 multicenter, open-label, dose escalation study for retinitis pigmentosa associated with Usher 1B.

2AAVB-039
CategoryInvestigational gene therapy candidate (clinical program)
Description

AAVB-039 is AAVantgarde's second investigational gene therapy product: an intra-retinal AAV8-intein mediated gene therapy delivering ABCA4, the gene associated with Stargardt disease (STGD1), the most common inherited retinal disorder caused by mutations in a single gene. It is being investigated in the CELESTE Phase 1/2 study in the US.

3AAVB-OPHTHA
CategoryPipeline program (preclinical expansion candidate)
Description

AAVB-OPHTHA represents AAVantgarde's next pipeline program targeting additional monogenic inherited retinal diseases (IRDs) with high unmet need, intended to expand the company's ophthalmology franchise beyond Usher 1B and Stargardt.

4AAVB-OTHER
CategoryPipeline program (preclinical expansion candidate, non-ophthalmic)
Description

AAVB-OTHER represents AAVantgarde's pipeline expansion into non-ophthalmic monogenic indications, exploring tissues outside the eye such as the inner ear and central nervous system using the company's large-gene delivery platforms.

5Dual Hybrid Platform
CategoryProprietary technology platform (large gene delivery)
Description

The Dual Hybrid Platform is AAVantgarde's proprietary AAV-based large gene delivery technology that splits a therapeutic transgene across two AAV vectors that recombine at the DNA level via a proprietary highly recombinogenic region and ITR-mediated concatemerization, producing a full-length mature mRNA inside the cell nucleus. It powers the AAVB-081 program for Usher 1B and is licensable to third parties (e.g., licensed to a US company for hereditary hearing loss).

6Intein Platform
CategoryProprietary technology platform (large gene delivery)
Description

The Intein Platform is AAVantgarde's proprietary AAV-based large gene delivery technology that uses two vectors each encoding one half of a target protein flanked by short split-intein sequences, enabling protein trans-splicing inside the cell to reconstitute large therapeutic proteins. It powers the AAVB-039 program for Stargardt disease and is licensable to third parties.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierMinorTypeOthersAnnounced on2026-03-24
Description

AAVantgarde CEO Natalia Misciattelli has been nominated by Idorsia for election to its Board of Directors at the May 2026 Annual General Meeting, reflecting her industry expertise rather than a commercial partnership between the two companies.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-11-21
Description

Manufacturing agreement under which AGC Biologics will produce AAVantgarde's dual-vector gene therapies for inherited retinal diseases (Stargardt and Usher syndrome-related retinitis pigmentosa) using AGC's BravoAAV™ platform. The collaboration supports clinical development in the US, UK, and Europe.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Foundational academic/research partner: AAVantgarde is a spin-off of TIGEM (Telethon Institute of Genetics and Medicine, a Telethon Foundation research centre in Pozzuoli, near Naples) and originated from research activities carried out there, including development of the Dual Hybrid and Intein AAV platforms by founder Alberto Auricchio.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Foundational partner: AAVantgarde Bio s.r.l. is described as a "Fondazione Telethon/UNINA spin-off company". Fondazione Telethon is a major Italian biomedical charity that has invested almost €600 million in funding over 2,700 rare-disease research projects. The Telethon Fund, managed by Sofinnova Partners, was a seed investor in AAVantgarde.

5University of Naples "Federico II" (UNINA)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

AAVantgarde is a joint spin-off of UNINA and TIGEM. Founder/CSO Professor Alberto Auricchio is Professor of Medical Genetics at University "Federico II" in Naples, Italy, and President of the European Society for Gene and Cell Therapy (ESGCT).

aavantgarde.com
6US company (Dual Hybrid licensee for hereditary hearing loss)
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

AAVantgarde has licensed its Dual Hybrid AAV gene therapy platform to a US company for application in hereditary hearing loss, representing an early-stage platform out-licensing revenue channel beyond the company's lead ophthalmology pipeline.

fondazionetelethon.it
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pioneering ocular AAV gene therapy company (acquired by Roche in 2019) that developed and commercialized Luxturna, the first FDA-approved gene therapy for an inherited retinal disease (RPE65 mutation). Direct comparable on AAV-based one-time subretinal gene therapy for IRDs with FDA Orphan and Breakthrough designations.

TypeDirect peer
Description

Clinical-stage AAV gene therapy developer focused on inherited retinal diseases (choroideremia, X-linked retinitis pigmentosa), acquired by Biogen for ~$800M in 2019. Most direct late-stage peer in subretinal AAV gene therapy for IRDs and a key prior-art benchmark for AAVantgarde's commercialization path.

TypeBroad incumbent
Description

Clinical and commercial-stage AAV gene therapy company with a broad NAV Technology platform and multiple ophthalmology programs (RGX-314 for wet AMD/nAMD via subretinal and suprachoroidal routes). Larger incumbent with overlapping AAV vector manufacturing and ocular delivery capabilities and a public market benchmark for AAVantgarde's potential valuation.

TypeDirect peer
Description

Clinical-stage gene therapy company developing ADVM-022 (intravitreal AAV.7m8-aflibercept) for wet AMD and diabetic macular edema. Closely comparable ocular AAV gene therapy peer with shared regulatory designations (FDA Fast Track) and a similar enterprise-value profile to AAVantgarde at clinical-stage.

TypeDirect peer
Description

Clinical-stage gene therapy company with multiple ocular programs (AAV-CNGB3, AAV-CNGA3 for achromatopsia, AAV-RPGR for X-linked retinitis pigmentosa) and in-house GMP manufacturing. Highly comparable peer given its portfolio of AAV-based therapies targeting IRDs and parallel regulatory trajectory.

6SparingVision
TypeDirect peer
Description

European clinical-stage biotech developing gene therapies for IRDs including retinitis pigmentosa (SPVN06, SPVN20). Closest European IRD gene therapy peer with comparable stage, fundraising profile (€75M Series B) and AAV-based approach.

TypeEmerging player
Description

European clinical-stage AAV gene therapy company with programs in ophthalmology (RPGR for X-linked retinitis pigmentosa) and CNS, using engineered AAV capsids. Comparable European gene-therapy peer at similar stage with an overlapping IRD pipeline.

TypeEmerging player
Description

Clinical-stage RNA-editing company (Axonys Therapeutics spinoff focus) developing therapies for IRDs including Stargardt disease (ultevursen for ABCA4 mutations) and Usher syndrome. Adjacent modality peer targeting the same patient populations as AAVantgarde via antisense oligonucleotides rather than AAV gene replacement.

TypeEmerging player
Description

Clinical-stage CRISPR gene-editing company that dosed the first in vivo CRISPR therapy (EDIT-101 for Leber congenital amaurosis 10, CEP290). Emerging modality peer that could compete with AAVantgarde's AAV approach for certain IRDs via in vivo editing.

TypeEmerging player
Description

Clinical-stage base-editing company with programs in sickle cell disease, alpha-1 antitrypsin deficiency and ocular diseases; exploring in vivo base editing for ABCA4 (Stargardt). Represents the next-generation editing modality that could displace dual-AAV gene therapy approaches for AAVantgarde's lead indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AAVantgarde Bio

Ophthalmic Gene Therapyaavantgarde.com

AAVantgarde Bio is a clinical-stage biotechnology company developing one-time subretinal gene therapies for inherited retinal disorders — Stargardt disease and Usher Syndrome Type 1B — using proprietary Dual Hybrid and Intein AAV platforms that deliver large therapeutic genes exceeding conventional AAV packaging capacity.

What AAVantgarde Bio does

AAVantgarde Bio s.r.l. is a clinical-stage biotechnology company founded in 2021 as a spin-off of the Telethon Institute of Genetics and Medicine (TIGEM) and the University of Naples 'Federico II', developing one-time subretinal gene therapies for inherited retinal disorders (IRDs) — specifically Stargardt disease (ABCA4 mutations) and retinitis pigmentosa associated with Usher Syndrome Type 1B (MYO7A mutations). The company is headquartered in Milan with operations in London and is led by CEO Natalia Misciattelli and founder/CSO Prof. Alberto Auricchio.

The company's core technology is two proprietary, AAV-based large-gene delivery platforms that overcome the ~4.7–5 kb cargo limit of conventional AAV vectors: the Dual Hybrid Platform, which splits a therapeutic transgene across two AAV8 vectors that reconstitute a full-length mature mRNA via ITR/HR-mediated concatemerization and splicing (used in AAVB-081 / LUCE-1 for Usher 1B); and the Intein-mediated Protein Trans-splicing Platform, which uses split inteins to reassemble large therapeutic proteins inside target cells (used in AAVB-039 / CELESTE for Stargardt). Both platforms have been validated in mice, pigs, non-human primates and human retinal organoids. The clinical pipeline comprises AAVB-081 (Phase 1/2 LUCE-1, fully enrolled) and AAVB-039 (Phase 1/2 CELESTE, IND-cleared), supported by the STELLA natural history study in ~120 Stargardt subjects. Pipeline placeholders AAVB-OPHTHA and AAVB-OTHER extend the platforms to additional IRDs and non-ophthalmic monogenic indications (inner ear, CNS).

AAVantgarde is currently pre-revenue. Funding to date totals approximately $202 million across a 2021 Sofinnova-Telethon seed, a €61M Series A in June 2023, and a $141M Series B in November 2025 co-led by Schroders Capital, Atlas Venture and Forbion, with new investors including Amgen Ventures. Future revenue is expected from commercialization of AAVB-081 and AAVB-039 and from platform out-licensing (a Dual Hybrid license for hereditary hearing loss has already been signed with a US company). Manufacturing is contracted to AGC Biologics; clinical operations span the US, UK and Europe; and the company partners with 14+ global patient advocacy organizations for trial recruitment and disease awareness.

AAVantgarde Bio firmographics

Firmographics
Name
AAVantgarde Bio
Legal name
AAVantgarde Bio s.r.l.
Website
https://aavantgarde.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Short description
AAVantgarde Bio is a clinical-stage biotechnology company developing one-time subretinal gene therapies for inherited retinal disorders — Stargardt disease and Usher Syndrome Type 1B — using proprietary Dual Hybrid and Intein AAV platforms that deliver large therapeutic genes exceeding conventional AAV packaging capacity.
Ownership category
akta.pro rank

AAVantgarde Bio industry classification

Industry
Product category
Ophthalmic Gene Therapy
akta.pro industry
PRIMARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Gene therapy development
  • Ophthalmic biotechnology
  • Adeno-associated virus vectors
  • Inherited retinal disorders
  • Clinical-stage biopharmaceutical

Where AAVantgarde Bio is headquartered

Location

Headquarters

HQ city
Milano
HQ country
Italy
HQ region
Europe

Offices2 records

Markets served

AAVantgarde Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pre-revenue clinical-stage development: AAVantgarde is currently pre-revenue, with no approved products. The company funds clinical development (LUCE-1, CELESTE, STELLA) entirely from venture capital and grants; future revenue is expected from commercialization of its lead gene therapies (AAVB-081 for Usher 1B and AAVB-039 for Stargardt) once approved, and from potential platform out-licensing to other indications.
  2. Platform out-licensing (Dual Hybrid): The Dual Hybrid platform has been licensed to a US company for hereditary hearing loss applications, generating potential upfront, milestone, and royalty income. This represents an early-stage licensing/royalty revenue stream derived from the company's proprietary AAV delivery technology.

Go-to-market motion4 records

Distribution channels4 records

Marketing channels7 records

AAVantgarde Bio product offering

Product offering

Core offering

AAVantgarde Bio is a clinical-stage biotechnology company developing investigational gene therapies for inherited retinal disorders (IRDs) using two proprietary dual-vector AAV delivery platforms — the Dual Hybrid Platform and the Intein Platform — that overcome the ~4.7–5 kb cargo limit of conventional AAVs to deliver large therapeutic transgenes such as MYO7A and ABCA4. The lead clinical programs are AAVB-081 (for retinitis pigmentosa associated with Usher Syndrome Type 1B) and AAVB-039 (for Stargardt disease), both pursued via subretinal administration of AAV8-based dual vectors.

Product overview

AAVantgarde Bio is a clinical-stage biotechnology company built around a platform-plus-candidates architecture: two proprietary large-gene AAV delivery platforms (the Dual Hybrid Platform and the Intein Platform) underpin a focused pipeline of investigational gene therapies. The Dual Hybrid Platform powers AAVB-081, the lead product for retinitis pigmentosa associated with Usher Syndrome Type 1B (Usher 1B), tested in the LUCE-1 Phase 1/2 trial; the Intein Platform powers AAVB-039, the second product for Stargardt disease, tested in the CELESTE Phase 1/2 trial and supported by the STELLA natural history study. The company is also extending its reach via two early pipeline placeholders — AAVB-OPHTHA (additional monogenic IRDs) and AAVB-OTHER (non-ophthalmic monogenic indications such as inner ear and CNS). The spin-off of Fondazione Telethon/TIGEM and University of Naples Federico II focuses the entire offering on restoring visual function and halting disease progression in IRDs caused by mutations in large genes that exceed conventional AAV packaging capacity.

Differentiator

Problem solved

Functional benefit

Brands

  • Dual Hybrid Platform: Proprietary AAV-based large gene delivery platform that splits a therapeutic transgene across two vectors and reassembles it at the DNA level via splice donor/acceptor signals and a highly recombinogenic region; used in the AAVB-081 program for Usher 1B.
  • Intein Platform
  • AAVB-081
  • AAVB-039

Products and services

  • AAVB-081 AAVB-081 is AAVantgarde's lead investigational gene therapy product: an intra-retinal AAV8-based dual hybrid gene therapy delivering MYO7A, the gene associated with Usher Syndrome Type 1B (Usher 1B). It is being investigated in the LUCE-1 Phase 1/2 multicenter, open-label, dose escalation study for retinitis pigmentosa associated with Usher 1B.
  • AAVB-039 AAVB-039 is AAVantgarde's second investigational gene therapy product: an intra-retinal AAV8-intein mediated gene therapy delivering ABCA4, the gene associated with Stargardt disease (STGD1), the most common inherited retinal disorder caused by mutations in a single gene. It is being investigated in the CELESTE Phase 1/2 study in the US.
  • AAVB-OPHTHA AAVB-OPHTHA represents AAVantgarde's next pipeline program targeting additional monogenic inherited retinal diseases (IRDs) with high unmet need, intended to expand the company's ophthalmology franchise beyond Usher 1B and Stargardt.
  • AAVB-OTHER AAVB-OTHER represents AAVantgarde's pipeline expansion into non-ophthalmic monogenic indications, exploring tissues outside the eye such as the inner ear and central nervous system using the company's large-gene delivery platforms.
  • Dual Hybrid Platform The Dual Hybrid Platform is AAVantgarde's proprietary AAV-based large gene delivery technology that splits a therapeutic transgene across two AAV vectors that recombine at the DNA level via a proprietary highly recombinogenic region and ITR-mediated concatemerization, producing a full-length mature mRNA inside the cell nucleus. It powers the AAVB-081 program for Usher 1B and is licensable to third parties (e.g., licensed to a US company for hereditary hearing loss).
  • Intein Platform The Intein Platform is AAVantgarde's proprietary AAV-based large gene delivery technology that uses two vectors each encoding one half of a target protein flanked by short split-intein sequences, enabling protein trans-splicing inside the cell to reconstitute large therapeutic proteins. It powers the AAVB-039 program for Stargardt disease and is licensable to third parties.

Quantifiable outcome

  • 15 Usher syndrome patients treated to date via the Dual Hybrid approach in the LUCE-1 study, with a very good safety profile and early efficacy signal reported
  • +3 more outcomes

Companies that use AAVantgarde Bio

Customer profile

Segments4 records

Ideal customer profiles2 records

AAVantgarde Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

AAVantgarde Bio partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered minor, flagship and core.

  • Idorsia (Board nomination of AAVantgarde CEO Natalia Misciattelli)minorOthers · 24 March 2026AAVantgarde CEO Natalia Misciattelli has been nominated by Idorsia for election to its Board of Directors at the May 2026 Annual General Meeting, reflecting her industry expertise rather than a commercial partnership between the two companies.
  • AGC BiologicsflagshipStrategic or Co-development Partner · 21 November 2025Manufacturing agreement under which AGC Biologics will produce AAVantgarde's dual-vector gene therapies for inherited retinal diseases (Stargardt and Usher syndrome-related retinitis pigmentosa) using AGC's BravoAAV™ platform. The collaboration supports clinical development in the US, UK, and Europe.
  • Telethon Institute of Genetics and Medicine (TIGEM)flagshipStrategic or Co-development Partner · 1 January 2021Foundational academic/research partner: AAVantgarde is a spin-off of TIGEM (Telethon Institute of Genetics and Medicine, a Telethon Foundation research centre in Pozzuoli, near Naples) and originated from research activities carried out there, including development of the Dual Hybrid and Intein AAV platforms by founder Alberto Auricchio.
  • Fondazione TelethonflagshipStrategic or Co-development Partner · 1 January 2021Foundational partner: AAVantgarde Bio s.r.l. is described as a "Fondazione Telethon/UNINA spin-off company". Fondazione Telethon is a major Italian biomedical charity that has invested almost €600 million in funding over 2,700 rare-disease research projects. The Telethon Fund, managed by Sofinnova Partners, was a seed investor in AAVantgarde.
  • University of Naples "Federico II" (UNINA)coreStrategic or Co-development Partner · 1 January 2021AAVantgarde is a joint spin-off of UNINA and TIGEM. Founder/CSO Professor Alberto Auricchio is Professor of Medical Genetics at University "Federico II" in Naples, Italy, and President of the European Society for Gene and Cell Therapy (ESGCT).
  • US company (Dual Hybrid licensee for hereditary hearing loss)coreOEM/ Whitelabel/ Licensing PartnerAAVantgarde has licensed its Dual Hybrid AAV gene therapy platform to a US company for application in hereditary hearing loss, representing an early-stage platform out-licensing revenue channel beyond the company's lead ophthalmology pipeline.

Scale indicators7 records

Recent moves7 records

Expansion highlights1 record

AAVantgarde Bio competitors and assessment

Company assessment

Direct peers

  • Spark Therapeutics: Pioneering ocular AAV gene therapy company (acquired by Roche in 2019) that developed and commercialized Luxturna, the first FDA-approved gene therapy for an inherited retinal disease (RPE65 mutation). Direct comparable on AAV-based one-time subretinal gene therapy for IRDs with FDA Orphan and Breakthrough designations.
  • Nightstar Therapeutics: Clinical-stage AAV gene therapy developer focused on inherited retinal diseases (choroideremia, X-linked retinitis pigmentosa), acquired by Biogen for ~$800M in 2019. Most direct late-stage peer in subretinal AAV gene therapy for IRDs and a key prior-art benchmark for AAVantgarde's commercialization path.
  • Adverum Biotechnologies: Clinical-stage gene therapy company developing ADVM-022 (intravitreal AAV.7m8-aflibercept) for wet AMD and diabetic macular edema. Closely comparable ocular AAV gene therapy peer with shared regulatory designations (FDA Fast Track) and a similar enterprise-value profile to AAVantgarde at clinical-stage.
  • MeiraGTx: Clinical-stage gene therapy company with multiple ocular programs (AAV-CNGB3, AAV-CNGA3 for achromatopsia, AAV-RPGR for X-linked retinitis pigmentosa) and in-house GMP manufacturing. Highly comparable peer given its portfolio of AAV-based therapies targeting IRDs and parallel regulatory trajectory.
  • SparingVision: European clinical-stage biotech developing gene therapies for IRDs including retinitis pigmentosa (SPVN06, SPVN20). Closest European IRD gene therapy peer with comparable stage, fundraising profile (€75M Series B) and AAV-based approach.

Broad incumbents

  • REGENXBIO: Clinical and commercial-stage AAV gene therapy company with a broad NAV Technology platform and multiple ophthalmology programs (RGX-314 for wet AMD/nAMD via subretinal and suprachoroidal routes). Larger incumbent with overlapping AAV vector manufacturing and ocular delivery capabilities and a public market benchmark for AAVantgarde's potential valuation.

Emerging players

  • Coave Therapeutics: European clinical-stage AAV gene therapy company with programs in ophthalmology (RPGR for X-linked retinitis pigmentosa) and CNS, using engineered AAV capsids. Comparable European gene-therapy peer at similar stage with an overlapping IRD pipeline.
  • ProQR Therapeutics: Clinical-stage RNA-editing company (Axonys Therapeutics spinoff focus) developing therapies for IRDs including Stargardt disease (ultevursen for ABCA4 mutations) and Usher syndrome. Adjacent modality peer targeting the same patient populations as AAVantgarde via antisense oligonucleotides rather than AAV gene replacement.
  • Editas Medicine: Clinical-stage CRISPR gene-editing company that dosed the first in vivo CRISPR therapy (EDIT-101 for Leber congenital amaurosis 10, CEP290). Emerging modality peer that could compete with AAVantgarde's AAV approach for certain IRDs via in vivo editing.
  • Beam Therapeutics: Clinical-stage base-editing company with programs in sickle cell disease, alpha-1 antitrypsin deficiency and ocular diseases; exploring in vivo base editing for ABCA4 (Stargardt). Represents the next-generation editing modality that could displace dual-AAV gene therapy approaches for AAVantgarde's lead indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

AAVantgarde Bio social profiles

Digital presence

AAVantgarde Bio compliance and trust

Trust signal

Compliance2 records

AAVantgarde Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AAVantgarde Bio leadership team

Management profile

Number of profiles

Profiles12 records

AAVantgarde Bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AAVantgarde Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AAVantgarde Bio

What does AAVantgarde Bio do?

AAVantgarde Bio is a clinical-stage biotechnology company developing investigational gene therapies for inherited retinal disorders (IRDs) using two proprietary dual-vector AAV delivery platforms — the Dual Hybrid Platform and the Intein Platform — that overcome the ~4.7–5 kb cargo limit of conventional AAVs to deliver large therapeutic transgenes such as MYO7A and ABCA4. The lead clinical programs are AAVB-081 (for retinitis pigmentosa associated with Usher Syndrome Type 1B) and AAVB-039 (for Stargardt disease), both pursued via subretinal administration of AAV8-based dual vectors.

Is AAVantgarde Bio a public or private company?

AAVantgarde Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was AAVantgarde Bio founded?

AAVantgarde Bio was founded in 2021. It employs 51 to 100 people.

Where is AAVantgarde Bio based?

AAVantgarde Bio is headquartered in Milano, Italy, in the Europe region.

How does AAVantgarde Bio make money?

Two revenue lines are on record. Pre-revenue clinical-stage development is the primary driver. The others are platform out-licensing (Dual Hybrid).

Who are AAVantgarde Bio's main competitors?

Direct peers on record are Spark Therapeutics, Nightstar Therapeutics, Adverum Biotechnologies, MeiraGTx and SparingVision. REGENXBIO is listed as a broad incumbent. Emerging players are Coave Therapeutics, ProQR Therapeutics, Editas Medicine and Beam Therapeutics.

Does AAVantgarde Bio have an API?

No public API is recorded for AAVantgarde Bio.

What industry is AAVantgarde Bio in?

AAVantgarde Bio's product category is Ophthalmic Gene Therapy. Its primary akta.pro industry code is HLAAACAG, Ophthalmology Gene Therapies, with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialAavantgarde To Present Progress Toward The First Treatment For Usher Syndrome Type 1B At EYENOVATE And Floretina 2026AAVantgarde will present clinical progress on its dual-AAV MYO7A gene therapy for Usher syndrome type 1B at EYENOVATE and Floretina 2026. The company will also discuss its approach to Stargardt disease and invite partnering discussions.Startuprad.io Startup PodcastBeyond BioNTech: Inside the Strüngmann Portfolio in 2026 (Antheia, AAVantgarde, Doctolib, and the Next Decade)Athos Service's post-BioNTech portfolio in 2026 focuses on gene therapy, AI-driven biomanufacturing, oncology platforms, and biosimilars. Key investments include AAVantgarde Bio's $141M Series B and Antheia's Series C-II, with the brothers' platform-company thesis intact. The portfolio signals a shift toward later-stage, de-risked biotech.Startuprad.io Startup PodcastThe Strüngmann Brothers: Net Worth & the BioNTech Family OfficeThe Strüngmann brothers sold Hexal to Novartis in 2005 for €5.65 billion, then anchored BioNTech with a €136.5–180 million seed in 2008. Their stake peaked at over $50 billion in 2021 and now holds ~43.5% worth ~€10 billion. They plan further BioNTech sales and new bets.PitchBookFirst-time raises help drive surge in Italian startup roundsItalian startups saw 225 VC rounds in Q1 2026, up 80% year-over-year, with first-time deals accounting for nearly two-thirds. The surge is driven by pension fund mandates requiring 5-10% allocation to VC, and 2026 is expected to surpass last year's total.BioSpaceAAVantgarde appoints Philip Lao as Senior Vice President of Business DevelopmentAAVantgarde Bio, a clinical-stage biotechnology company developing therapies for inherited retinal diseases, announced the appointment of Philip Lao as Senior Vice President of Business Development, effective immediately. Lao previously served as Head of Business Development at Adverum Biotechnologies, where he led the company's sale to Eli Lilly in December 2025, and brings prior transaction experience from roles at Novartis, Pfizer, and Takeda. The appointment is intended to strengthen AAVantgarde's strategic partnership and commercial capabilities as it advances its pipeline of retinal disease therapies.DrugdiscoverynewsGene therapy startups push past old limits to reach more patientsGene therapy startups are advancing innovative delivery systems to treat more patients effectively, moving beyond proof-of-concept to scalable solutions. Genespire and AAVantgarde Bio exemplify efforts to improve gene therapy durability and transgene capacity, respectively.BlueridgenowItaly–U.S. Biotech, Pharma and Investment Leaders Together in San Francisco During JPM Week at ‘Italy on the Move’The ninth edition of 'Italy on the Move,' an Italian trade promotion event for the biotech, pharma, and investment sectors, took place on January 14, 2026, in San Francisco alongside the 44th J.P. Morgan Annual Healthcare Conference. The event convened over 200 institutional representatives and industry leaders to strengthen collaboration between Italian and U.S. life sciences ecosystems, featuring a roundtable and pitch sessions with executives from companies including Genespire, Gossamer Bio, AAVantgarde, Genenta Science, and Eli Lilly. Market data presented highlighted Italy's life sciences industry generating over €237 billion in annual turnover, representing nearly 10% of national GDP, with pharmaceutical exports reaching €54 billion in 2024.GlobeNewswireAAVantgarde to Present at the 44th Annual J.P. Morgan Healthcare ConferenceAAVantgarde Bio will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, in San Francisco. CEO Dr. Natalia Misciattelli will highlight progress on AAVB-039 for Stargardt disease and AAVB-081 for retinitis pigmentosa associated with Usher syndrome type 1B.CGTLiveAAVantgarde’s Stargardt Gene Therapy AAVB-039 Garners FDA Orphan Drug Designation, Cleared for Trial in UKAAVantgarde received FDA Orphan Drug Designation for its Stargardt gene therapy, AAVB-039. The company has also been cleared to proceed with clinical trials in the United Kingdom.